Co‐expression of NKG2A and PD‐1 has been documented on CD8+ TILs, and current investigations are exploring the anti‐tumour potential of this combination of ICIs in clinical trials (André et al., 2018; Montfoort et al., 2018). The gene discussed is CD8A; the disease is neoplasm.